lilly_building_with_american_flag_web

Lilly’s Trulicity reduces major cardiovascular events in “ambitious” trial of type 2 diabetes

pharmafile | November 7, 2018 | News story | Research and Development |  Eli Lilly, Trulicity, cardiovascular events, pharma, type 2 diabetes 

Eli Lilly has revealed new data on Trulicity (dulaglutide), showing that glucagon-like peptide-1 (GLP-1) receptor agonist achieved its primary endpoint and “significantly reduced” the occurrence of major cardiovascular events (MACE) in patients with type 2 diabetes mellitus.

In the study, MACE included cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke.

The REWIND trial set itself apart from many similar studies by merit of its small population of participants with establish cardiovascular disease – just  31% – which allowed for a more insightful look into Trulicity’s effects on a broader range of those with type 2 diabetes.  

Additionally, the study had the longest median follow-up period of any CV outcomes  trial in the GLP-1 receptor agonist class, at more than five years.

Advertisement

“The REWIND study was ambitious, assessing whether dulaglutide could protect a broad range of people with type 2 diabetes, including a high proportion of patients without established cardiovascular disease, from experiencing a cardiovascular event,” explained Dr Arash Tahbaz, Senior Medical Director at Eli Lilly and Company UK and Northern Europe. “The initial study outcomes are compelling and we look forward to analysing and reporting all of the data.”

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Lilly opens fourth US Gateway Labs site

Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

The Gateway to Local Adoption Series

Latest content